
BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Marsha A. Raebel	POSITION TITLE Clinical Associate Professor Pharmacotherapy Research Manager		
eRA COMMONS USER NAME MARAEBEL			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
South Dakota State University, Brookings, S.D.	BS; BS	1976	Pharmacy; Microbiology
University of Texas at Austin and the U of Texas Health Sciences Center, San Antonio, TX	PharmD	1979	Pharmacotherapy
University of Colorado at Denver and Health Sciences Center, Denver, CO		2005	Certificate Program in Public Health

A. Positions and Honors.

Professional Experience

1979-1980 Assistant Professor, College of Pharmacy, The University of Minnesota
1979-1980 Inpatient Drug Education Coordinator and Clinical Pharmacist, Minneapolis Veterans Administration Medical Center
1980-1993 Coordinator of Drug Information and Clinical Pharmacy and Clinical Pharmacy Specialist in Medicine and Infectious Diseases, Scott and White Hospital and Clinics
1981-1988 Assistant Professor, Department of Internal Medicine, Texas A&M University College of Medicine
1983-1990 Clinical Assistant Professor, College of Pharmacy, The University of Texas at Austin
1988-1993 Associate Professor, Department of Internal Medicine, Texas A&M University College of Medicine
1990-1993 Clinical Associate Professor, College of Pharmacy, The University of Texas at Austin
1993-1997 Manager of Clinical Pharmacy Services, Kaiser Permanente Rocky Mountain Division
1995-2004 Clinical Associate Professor, School of Pharmacy, U of Colorado Health Sciences Center
1997-1998 Clinical Pharmacy Specialty Services, Research and Education Administrator, Kaiser Permanente Rocky Mountain Division
1998-2000 Pharmacy Research and Education Manager, Kaiser Permanente of Colorado (KPCO)
2000-2005 Pharmacotherapy Research Manager, KPCO
2005-present Investigator/Pharmacotherapy and Clinical Trials Research Manager, KPCO
2004-present Clinical Associate Professor, School of Pharmacy, U of Colorado at Denver

Honors

1979 Rho Chi
1989 TSHP Research and Education Foundation Research Award for Excellence in Research
1989 Fellow, American College of Clinical Pharmacy
1990 Scientific Exhibit Award, 84th Annual Scientific Assembly of the Southern Medical Association
1991 Outstanding Service Award, Institutional Research Committee, Scott and White
1992, 1999 Board Certified Pharmacotherapy Specialist (BCPS), Board of Pharmaceutical Specialties
1993 Service Award, Institutional Review Board, Scott and White
1997 Summit Excellence Award, Kaiser Permanente Rocky Mountain Division
1998, 1999 CARE Project of the Year Nominee, Kaiser Permanente Rocky Mountain Division
2001 Permanente Medical Group Excellent Service Award Finalist, Kaiser Permanente of Colorado
2002 Summit Excellence Award, Kaiser Permanente of Colorado
2004 Distinguished Alumnus, South Dakota State University College of Pharmacy
2005 CARE Project of the Year (Improving Medication Safety), Kaiser Permanente of Colorado

B. Selected peer-reviewed publications (in chronological order).

Research Publications (within last five years)

1. Long CL, **Raebel MA**, Price DW, Magid DJ. Compliance with to Dosing Guidelines in Patients with Chronic Kidney Disease. *Ann Pharmacother* 2004;38:853-8.
2. Porter JA, **Raebel MA**, Conner DA, Lanty FA, Vogel EA, Gay EC, Merenich JA. The Long-Term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) Study: Evaluating the Role of Drug Therapy within a Weight Management Program in a Group-Model Health Maintenance Organization. *Am J Manag Care*. 2004;10(6):369-76.
3. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein FA, Fortman K, McPhillips H, **Raebel MA**, Roblin D, Smith DH, Yood MU, Morse AN, Platt R. Prescription Drug Use in Pregnancy. *Am J Obstet Gynecol*; 2004;191:398-407.
4. **Raebel MA**, Malone DC, Conner DA, Xu S, Porter JA, Lanty FA. Health services use and health care costs of obese and non-obese individuals. *Arch Intern Med*; 2004;164:2135-40.
5. Stille CJ, Andrade SE, Huang S, Nordin J, **Raebel MA**, Go AS, Chan KA, Finkelstein JA. Increased use of second-generation macrolide antibiotics for children in nine US health plans. *Pediatrics*. 2004;114:1206-11.
6. **Raebel MA**. Treatment of Respiratory Infections in Ambulatory Managed Care Patients. *Ann Pharmacother*. 2005;39:699-705
7. Malone DC, **Raebel MA**, Porter JA, Lanty FA, Conner DA, Gay EC, Vogel EA, Merenich JA. Cost Effectiveness of Sibutramine in the Long-Term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) Study: Evaluating the Role of Drug Therapy within a Weight Management Program. *J Manag Care Pharm*. 2005;11(6):458-68.
8. **Raebel MA**. Witt DM, Carroll NM, Magid DJ. Warfarin Monitoring in Ambulatory Older Individuals receiving Antimicrobial Therapy. *Pharmacother* 2005. 25(8):1055-61.
9. **Raebel MA**, Ellis JL, Andrade SE. Evaluation of Gestational Age and Admission Data Assumptions Used to Determine Prenatal Drug Exposure from Administrative Data. *Pharmacoepidemiol Drug Saf*. 2005;14(12):829-36.
10. Simon SR, Andrade SE, Ellis JL, Nelson WW, Gurwitz JH, Lafata JE, **Raebel MA**. Baseline Laboratory Monitoring of Cardiovascular Medicines in Ambulatory Care among Elderly HMO Enrollees in the U.S. *J Am Geriatr Soc*. 2005;53(12):2165-69.
11. **Raebel MA**, Lyons EE, Andrade SE, Chan KA, Chester EA, Davis RL, Ellis JL, Feldstein A, Gunter MJ, Lafata JE, Long CL, Magid DJ, Selby JV, Simon SS, Platt R. Laboratory Monitoring of High Risk Drugs at Initiation of Therapy in Ambulatory Care. *J Gen Intern Med* 2005;20(12):1120-6.
12. **Raebel MA**, Lyons EE, Bodily MA, Chester EA, Kelleher JA, Long CL, Miller C, Magid DJ,. Improving Laboratory Monitoring at Initiation of Drug Therapy: A Randomized Trial. *Arch Intern Med*. 2005;165:2395-2401.
13. **Raebel MA**, McClure DL, Simon SR, Chan KA, Feldstein A, Gunter MJ, Harrold L, Nelson WW, Platt R. Serum Creatinine Monitoring During Allopurinol Therapy in Ambulatory Patients. *Ann Pharmacother* 2006;40:386-91. Authors reply to letter to the editor: **Raebel MA**, McClure DL, Simon SR. Author's Reply to letter received about Serum Creatinine Monitoring During Allopurinol Therapy in Ambulatory Patients. *Ann Pharmacother* 2006;40:1474.
14. Wagner AK, Chan KA, Dashevsky I, **Raebel MA**, Andrade SE, Lafata JE, Davis RL, Gurwitz JH, Soumerai SB, Platt R. FDA Drug Prescribing Warnings: Is the Black Box Half Empty or Half Full? *Pharmacoepidemiol Drug Saf* 2006;15:369-86.
15. Allen LaPointe NM, Curtis, LH, Chan, KA, Kramer, JM, Lafata, JE, Gurwitz, JH, **Raebel MA**, Platt R. Frequency of High-Risk Use of QT-Prolonging Medications. *Pharmacoepidemiol Drug Saf* 2006;15:361-8.
16. Lafata JE, Schultz L, Simpkins J, Chan KA, Horn JR, Kaatz S, Long C, Platt R, **Raebel MA**, Smith DH, Xi H, Yood MU. Potential Drug-Drug Interactions in the Outpatient Setting. *Med Care* 2006;44(6):534-541.
17. **Raebel MA**, Chester EA, Newsom EE, Lyons EE, Kelleher JA, Long C, Miller C, Magid DJ. Randomized Trial to Improve Laboratory Safety Monitoring of Drug Therapy in Ambulatory Patients. *Pharmacother* 2006;26:619-25.
18. Hess LM, **Raebel MA**, Conner DA, Malone D. The Measurement of Adherence in Administrative Databases. *Ann Pharmacother* 2006;40:1280-88.

19. Harrold LR, Yood RA, Mikuls TR, Andrade SE, Davis J, Fuller J, Chan KA, Roblin D, **Raebel MA**, Von Worley A, Platt R, Saag KG. Sex differences in gout epidemiology, evaluation and treatment. *Ann Rheum Dis* 2006;65:1368-72
20. Andrade SE, **Raebel MA**, Morse AN, Davis RL, Chan KA, Finkelstein JA, Fortman K, McPhillips H, Roblin D, Smith DH, Yood MU, Platt R, Gurwitz JH. Use of Prescription Medications with a Potential for Fetal Harm among Pregnant Women. *Pharmacoepidemiol Drug Saf* 2006;5:546-54.
21. **Raebel MA**, Carroll NM, Andrade SE, Chester EA, Lafata JE, Feldstein A, Gunter MJ, Nelson WW, Simon SR, Chan KA, Davis RL, Platt R. Narrow Therapeutic Range Drug Monitoring in Ambulatory Care. *Am J Manag Care* 2006;12:268-74.
22. Palen TE, **Raebel MA**, Lyons E, Magid DM. Evaluation of Laboratory Monitoring Alerts within a Computerized Physician Order Entry System for Medications Orders. *Am J Manag Care* 2006;12:389-95.
23. Feldstein AC, Smith DH, Perrin N, Yang X, Rix M, **Raebel MA**, Magid DJ, Simon SR, Soumerai SB. Several interventions improved therapeutic monitoring: a randomized trial. *Arch Intern Med* 2006;166:1848-54.
24. **Raebel MA**, Carroll NC, Simon SR, Andrade SE, Feldstein AC, Lafata JE, Nelson WW, Chan KA, Gunter JM, Tolsma D, Platt R. Hepatic and Thyroid Monitoring in Ambulatory Patients Prescribed Amiodarone in 10 HMOs. *J Manag Care Pharm* 2006;12(8):656-64.
25. Harrold LR, Saag KG, Yood RA, Mikuls TR, Andrade SE, Fouayzi H, Davis J, Chan KA, **Raebel MA**, Von Worley A, Platt R. Validity of gout diagnoses in administrative data. *Arth Care Res* 2007;57(1):103-8.
26. **Raebel MA**, McClure DL, Simon SR, Chan KA, Feldstein A, Andrade SE, Lafata JE, Roblin D, Davis RL, Gunter MJ, Platt R. Laboratory Monitoring of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Ambulatory Patients. *Pharmacoepidemiol Drug Saf* 2007;16:55-64.
27. Elston Lafata J, Simpkins J, Kaatz S, Horn JR, **Raebel MA**, Schultz L, Smith DH, Yood MU, and the HMO Research Network CERTs. Medical Record Documentation Regarding Drug-Drug Interactions in Ambulatory Care. What do medical records tell us about potentially harmful co-prescribing? *Jt Comm J Qual Patient Saf* 2007 Jul;33(7):395-400.
28. **Raebel MA**, McClure DL, Andrade SE, Chan KA, Davis RL, Feldstein AC, Gunter MJ, Lafata JE, Nelson WW, Simon SR, Roblin D, Platt R. Laboratory Evaluation of Potassium and Creatinine Among Ambulatory Patients Prescribed Spironolactone: Are We Monitoring for Hyperkalemia? *Ann Pharmacother* 2007;41:193-200.
29. **Raebel MA**, Carroll NM, Kelleher JA, Chester EA, Berga S, Magid DJ. Randomized Trial to Improve Prescribing Safety during Pregnancy. *J Am Med Inform Assoc.* 2007;14:440-450.
30. Davis RL, Rubanowice D, McPhillips H, **Raebel MA**, Andrade SE, Smith D, Yood M, Platt R. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. *Pharmacoepidemiol Drug Saf* 2007;16:1086-94.
31. Mazor KM, Sabin J, Boudreau D, Goodman M, Gurwitz JH, Herrinton L, **Raebel M**, Roblin D, Smith D, Meterko V, Platt R. Cluster Randomized Trials: Opportunities and Barriers identified by Leaders of Eight Health Plans. *Med Care* 2007;45(10) Suppl 2:S29-S37.
32. **Raebel MA**, Charles J, Dugan J, Carroll NM, Korner EJ, Brand DW, Magid DJ. Randomized Trial to Improve Prescribing Safety among Ambulatory Elderly Patients. *J Am Geriatr Soc* 2007;55:977-985.
33. Brown JS, Kulldorff M, Chan KA, Davis RL, Graham D, Pettus PT, Andrade SA, **Raebel MA**, Herrinton L, Roblin D, Boudreau D, Smith D, Gurwitz JH, Gunter MJ, Platt R. Early detection of adverse drug events within population-based health networks: Application of sequential testing methods. *Pharmacoepidemiol Drug Saf.* 2007;16(12):1275-84.
34. Andrade SE, **Raebel MA**, Brown J, Lane K, Livingston J, Boudreau D, Goodman M, Roblin D, Smith DH, Willy M, Staffa JA, Platt R. Use of Antidepressant Medications During Pregnancy: A Multi-site Study. *Am J Obstet Gynecol* (in press).
35. Andrade SE, **Raebel MA**, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Dal Pan GJ, Scott PE, Platt R. Outpatient Use of Cardiovascular Drugs During Pregnancy. *Pharmacoepidemiol Drug Saf* 2008;17(3):240-7.
36. Price DW, **Raebel MA**, Conner DA, Wright LA. Prescribers' and Organizational Leaders' Preferences for Education about Heavily-Marketed Drugs. *Permanente J* 2008;12(2):28-35.

Books and Book Chapters (within last 5 years)

1. Magid DJ, Estabrooks PA, Brand DW, **Raebel MA**, Palen TE, Steiner JS, Korner EJ, Bates DW, Platt R, Glasgow RE. Translating Patient Safety Research into Clinical Practice. In: Advances in Patient Safety: From Research to Implementation. Vol 2. AHRQ Publication Nos. 050021 (1-4). February 2005. Agency for Healthcare Research and Quality, Rockville, MD. <http://www.ahrq.gov/qual/advances/>
2. Pai MP, Mercier RC, **Raebel MA**. Viral Hepatitis. In: Pharmacotherapy. A Pathophysiologic Approach. 6th ed. DiPiro JT, Talbert RL, Yee GC et al (Editors). McGraw-Hill: New York. 2005;737-759
3. Selby JV, Smith DH, Johnson E, **Raebel MA**, Friedman GD, MacFarland BH. Kaiser Permanente Medical Care Program. In Pharmacoepidemiology. Strom B (editor). 2005:241-59.
4. Chan KA, Davis RL, Gunter MJ, Gurwitz JH, Herrinton LJ, Nelson WW, **Raebel MA**, Roblin DQ, Smith DH, Platt R. The HMO Research Network. In: Pharmacoepidemiology. Strom B (editor). 2005:261-9.
5. **Raebel MA**, Chester EA, Brand DW, Magid DJ. Imbedding Research in Practice to Improve Medication Safety. AHRQ Advances in Patient Safety (in press). 2008.

C. Research Support.

Ongoing

Marsha Raebel (PI)

09/25/07 – 07/31/09

National Institute for Diabetes, Digestive, and Kidney Diseases 1R21 DK075076-01A1

Diabetes and Drug-Associated Hyperkalemia: Effect of Laboratory Monitoring

This study assesses associations between receipt and timing of potassium monitoring and the occurrence of hyperkalemia-associated adverse events in patients with diabetes who are prescribed angiotensin converting enzyme inhibitors, angiotensin receptor blockers and/or aldosterone receptor antagonists.

Role: Principal Investigator

Richard Platt (PI)

09/01/07 – 08/31/11

Agency for Healthcare Research and Quality

1U 18HS016955

HMO Research Network Centers for Education and Research in Therapeutics (CERTs 3)

The aims of this project are to enhance the ability of the HMO Research Network and collaborating health plans to advance therapeutics knowledge by leveraging data sources within a large, generalizable population and to develop and implement new methods for disseminating and promoting best therapeutic practices.

Role: Co-Investigator

Richard Platt (PI)

09/29/07 – 09/28/09

AHRQ

CERTs FDA Safety Surveillance Studies

Currently Approved Medications for ADHD and the Risk of Serious Cardiovascular Outcomes

The major goals of this study are to determine whether incidence rates and risk ratios for selected

cardiovascular events and arrhythmias in children/adolescents and adults exposed to medications used to treat ADHD are elevated when compared to periods of non-treatment and with a random sample of non-users.

Role: Co-Investigator

Marsha Raebel (PI)

04/01/08 – 03/31/09

Kaiser Permanente Colorado

Health Care Utilization and Outcomes of KPCO Medicare Members during the First Calendar Year of Medicare Part D: Phase II

In this observational study we compare 1) utilization patterns of KPCO Medicare members over the three-year period from one year before through two years after implementation of the Medicare Part D drug benefit threshold, and 2) KPCO Medicare members for whom repeatedly reaching the drug benefit threshold is associated with increased utilization with those Medicare members who reach the threshold, but do not have associated increases in utilization.

Role: Principal Investigator